Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Ovarian cancer (OC) Gynecological cancers have the highest fatality rate. Cisplatin, also known as CDDP (cis dichloro diammine platinum), encourages DNA chain and interchain crosslinks, obstructs DNA replication and stimulates cell death. Platinum has emerged as the key medication for the treatment of OC, whereas CDDP has been utilized as a chemotherapeutic medicine since the end of the 1970s. In order to validate the role of overexpression of COX‐2 as a prognostic marker in patients with ovarian cancer in the Indian subcontinent, this study examined the relationship between COX‐2 expressions in human ovarian cancer as well as its association with other recognized prognostic indicators like age, menopausal status, tumour size, stage and grade. Using the Western Blot Method, ovarian tissue's COX‐2 protein expression was evaluated. In the control group, COX‐2 expression was not present. Although the proportion of COX‐2 positive tumors was higher in patients over 50 years old [25 (51.0%)], this was not statistically significant (p = 0.07); postmenopausal status [36 (73.5%)], p<0.01, 7 (14.3%) patients with stage I, 14 (28.5%) patients with stage II, 19 (38.8%) patients with stage III and 9 (18.4%) patients with stage IV disease had COX‐2 positive tumors. There were statistically substantially more COX‐2 positive tumors in grade I (4 patients, 8.2%), grade II (12 patients, 24.5%) and grade III (33 patients, 67.3%) than in grade I (COX‐2 negative tumors). In our investigation, COX‐2 was positive in 55.1% (27) of T3 tumors, 20.4% (12) of T2 tumors and 20.4% (10) of T1 tumors. COX‐2 expression is associated with established indicators of poor prognosis such as postmenopausal status, age >50 years, advanced stage of disease, large tumour size and higher grade. The risk of COX‐2 positivity was found to be 3.54 times greater for postmenopausal status and 6.70 times greater for tumours size T2. As a result, COX‐2 expression suggests an aggressive tumor biology and may be a key prognostic indicator.
How to cite this article:
Sambhunath Bandyopadhyay, Bidisha Roychoudhury, Srijoni Chowdhury and Debarshi Jana. Role of Cyclooxygenase 2 (COX‐2) in Prognosis of Ovarian Cancer.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.10.91.95
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.10.91.95